Inhibitors of PARP: Number crunching and structure gazing

Selective inhibitors of PARP1 and PARP2 (PARP1/2) are used to treat cancer patients with deficiencies in the repair of DNA via homologous recombination. Here we provide a perspective on the reported potencies of the most studied of these inhibitors (olaparib, talazoparib, niraparib, rucaparib, and v...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudolph, Johannes, Jung, Karen, Luger, Karolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931346/
https://www.ncbi.nlm.nih.gov/pubmed/35259019
http://dx.doi.org/10.1073/pnas.2121979119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931346/
https://www.ncbi.nlm.nih.gov/pubmed/35259019
http://dx.doi.org/10.1073/pnas.2121979119

Ejemplares similares